Clinical Study to Evaluate the Efficacy of Prasterone Treatment for Atrophy Vulvovaginal in Postmenopausal Women With Vulvar / Vestibular Pain

Inclusion Criteria: * Women over 45 years of age with at least one year of amenorrhea and at least one symptom of vulvovaginal atrophy of moderate and / or severe intensity. * Women with moderate to severe vulvar / vestibular pain * Women without symptoms or signs of acute vaginal infection. * Women without symptoms of urinary infection and a negative urine strip result. * Woman willing to carry out the study procedures and comply with the visits. * Woman who signs the Informed Consent. Exclusion Criteria: * Hormone treatment in the last three months for vulvovaginal atrophy * Treatment with vaginal moisturizers in the last week for vulvovaginal atrophy * Laser treatment in the last 6 months. * Acute and recurrent urinary tract infections in the last 3 months. * Acute genital infections (herpes, candida, etc) * Personal history of cancer at any level * Present alterations in the area to be treated, such as lacerations, abrasions or ulcers (resolution time at the medical discretion) * Decompensated non-communicable chronic diseases (Diabetes Mellitus, Heart Disease ...) * Participation in a clinical study 3 months before inclusion or during this study. * Hypersensitivity to the active principle or any of the excipients * Undiagnosed vaginal bleeding. * Untreated endometrial hyperplasia * Acute liver disease or a history of liver disease while liver function tests remain impaired. * Current diagnosis or history of venous thromboembolism (deep vein thrombosis, pulmonary embolism) * Known thrombophilic disorders (protein C, protein S, or antithrombin deficiency) * Current or recent diagnosis of arterial thromboembolic disease (angina, myocardial infarction) * Porphyria